Last update 21 Nov 2024

Disodium Phosphate/Monosodium Phosphate

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dibasic Sodium Phosphate Hydrate/Sodium Dihydrogen Phosphate Dihydrate, Monobasic sodium phosphate monohydrate/Dibasic sodium phosphate anhydrous, disodium phosphate/Monosodium phosphate

+ [6]

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hypophosphatemia

Inactive Indication

Intestinal preparation

Originator Organization

Purzer Pharmaceutical Co. Ltd.

Active Organization

Zeria Pharmaceutical Co., Ltd.

Inactive Organization

Salix Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

US (16 Mar 2006),

Intestinal preparation

Regulation-

Structure

Molecular FormulaH6Na2O8P2

InChIKeyIMCWTZFHELIXTH-UHFFFAOYSA-N

CAS Registry39413-44-0

100 Clinical Results associated with Disodium Phosphate/Monosodium Phosphate

100 Translational Medicine associated with Disodium Phosphate/Monosodium Phosphate

100 Patents (Medical) associated with Disodium Phosphate/Monosodium Phosphate

Literatures (Medical) associated with Disodium Phosphate/Monosodium Phosphate

03 Apr 2015·Drug Development and Industrial PharmacyQ4 · MEDICINE

Reduction of tablet weight variability by optimizing paddle speed in the forced feeder of a high-speed rotary tablet press

Q4 · MEDICINE

Article

Author: Elisabeth Peeters ; Thomas De Beer ; Chris Vervaet ; Jean Paul Remon

CONTEXTTableting is a complex process due to the large number of process parameters that can be varied. Knowledge and understanding of the influence of these parameters on the final product quality is of great importance for the industry, allowing economic efficiency and parametric release.OBJECTIVEThe aim of this study was to investigate the influence of paddle speeds and fill depth at different tableting speeds on the weight and weight variability of tablets.MATERIALS AND METHODSTwo excipients possessing different flow behavior, microcrystalline cellulose (MCC) and dibasic calcium phosphate dihydrate (DCP), were selected as model powders. Tablets were manufactured via a high-speed rotary tablet press using design of experiments (DoE). During each experiment also the volume of powder in the forced feeder was measured.RESULTS AND DISCUSSIONAnalysis of the DoE revealed that paddle speeds are of minor importance for tablet weight but significantly affect volume of powder inside the feeder in case of powders with excellent flowability (DCP). The opposite effect of paddle speed was observed for fairly flowing powders (MCC). Tableting speed played a role in weight and weight variability, whereas changing fill depth exclusively influenced tablet weight.CONCLUSIONThe DoE approach allowed predicting the optimum combination of process parameters leading to minimum tablet weight variability. Monte Carlo simulations allowed assessing the probability to exceed the acceptable response limits if factor settings were varied around their optimum. This multi-dimensional combination and interaction of input variables leading to response criteria with acceptable probability reflected the design space.

01 Jan 2014·Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology

Therapeutic use of oral sodium phosphate (phosribbon(®) combination granules) in hereditary hypophosphatemic rickets.

Article

Author: Kitaoka, Taichi ; Naito, Yuki ; Ozono, Keiichi ; Shimura, Asami ; Hasegawa, Yukihiro ; Adachi, Masanori ; Minagawa, Masanori ; Namba, Noriyuki ; Asakura, Yumi ; Kazukawa, Itsuro

Oral sodium phosphate formulations indicated for hypophosphatemia are commercially available worldwide. In Japan, however, many medical institutes have used hospital dispensary or foreign over-the-counter formulations because no such medication with an indication covered by the health insurance system is domestically available. To address this problem, we initiated the development of Phosribbon(®). The present study evaluated the efficacy and safety of Phosribbon(®) in 16 patients with hereditary hypophosphatemic rickets. The optimal dosage and an administration pattern were also investigated. Administration of the agent resulted in an increase in the level of serum phosphorus in all patients, which implied that the employed dosage was appropriate. The dosage and administration pattern were adjusted based on comprehensive considerations, including changes in clinical laboratory values such as serum phosphorus, alkaline phosphatase and intact PTH, the dosage of a concomitantly administered activated vitamin D formulation and characteristics of individual patients. Adverse drug reactions were observed in 2 patients, neither of which were serious or necessitated therapy dose reduction or discontinuation. We conclude that Phosribbon(®) is a safe and effective treatment for patients with hypophosphatemic rickets and that dose adjustment in this therapy can be guided by the results of regular clinical examination and renal ultrasonography. (ClinicalTrials.gov Identifier: NCT01237288).

01 Sep 2011·Drug Development and Industrial PharmacyQ4 · MEDICINE

Modulation of drug (metoprolol succinate) release by inclusion of hydrophobic polymer in hydrophilic matrix

Q4 · MEDICINE

Article

Author: Jasmina Khanam ; Anirbandeep Bose ; Sabahuddin Siddique

The objective of this study was to develop sustained release (SR) matrix tablets of metoprolol succinate (MS), by using different polymer combinations and fillers, to optimize by response surface methodology and to evaluate biopharmaceutical parameters of the optimized product. Matrix tablets of various combinations were prepared with cellulose-based polymers: hydroxy propyl methyl cellulose (HPMC) and ethyl cellulose (EC); and lactose and dibasic calcium phosphate dihydrate (DCP) as fillers. Study of pre-compression and post-compression parameters facilitated the screening of a formulation with best characteristics that underwent here optimization study by response surface methodology (Central Composite Design). The optimized tablet was subjected to further study like scanning electron microscopy, swelling study and in vivo study in rabbit model. Both in vitro and in vivo study revealed that combining of HPMC K100M (21.95%) with EC (8.85%), and use of DCP as filler sustained the action up to 12 h. The in vivo study of new SR tablets showed significant improvement in the oral bioavailability of MS in rabbits after a single oral dose of 25 mg. The delayed T(max) and lower C(max) indicated a slow and SR of MS from the optimized matrix tablets in comparison with the immediate release dosage form. The developed SR (MS) tablet of improved efficacy can perform therapeutically better than conventional tablet.

News (Medical) associated with Disodium Phosphate/Monosodium Phosphate

08 Jun 2007

·www.biospace.com

Salix Pharmaceuticals, Ltd. Announces Imminent Launch of Visiclear(R) in Japan

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Zeria Pharmaceutical Co., Ltd. of Tokyo, Japan plans to launch Visiclear® Tablets for colon cleansing in Japan on June 15, 2007. Visiclear, or sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous, tablets are marketed in the United States under the trade name VISICOL®. In August 2001, InKine Pharmaceutical Company, Inc. (acquired by Salix in September 2005) licensed exclusive commercial rights in Japan to the product, the first approved and marketed tablet formulation colon cleansing agent, to Zeria.

100 Deals associated with Disodium Phosphate/Monosodium Phosphate

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypophosphatemia	JP	Zeria Pharmaceutical Co., Ltd.	25 Dec 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Disodium Phosphate/Monosodium Phosphate

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation